Table 3 Comparing the experiences between retina specialists from India and other parts of the globe:
From: Real-world practice patterns of eplerenone use for central serous chorioretinopathy
Variable | India (n = 95) | Rest of the World (n = 54) | P value | |
|---|---|---|---|---|
Years of clinical experience | 13.96 ± 9.17 | 17.44 ± 9.307 | 0.019 | |
No. of new patients with CSCR seen in a month (n, %) | 0–10 | 61 (64) | 34 (63) | 0.861 |
11–20 | 26 (27) | 14 (26) | ||
> 20 | 8 (9) | 6 (11) | ||
Acute cases of CSCR seen in a month (n, %) | 0–10 | 87 (92) | 52 (96) | 0.072 |
11–20 | 7 (7) | 0 (0) | ||
> 20 | 1 (1) | 2 (4) | ||
Chronic cases of CSCR seen in a month (n, %) | 0–10 | 88 (93) | 37 (69) | 0.001 |
11–20 | 7 (7) | 13 (24) | ||
> 20 | 0 (0) | 4 (7) | ||
Availability of PDT in practice (n, %) | No, not available | 76 (80) | 18 (33) | < 0.001 |
Yes, but difficult to get the drug | 18 (19) | 28 (52) | ||
Yes, easily available | 1 (1) | 8 (15) | ||
Effect of VICI trial results on eplerenone usage (n, %) | Yes | 14 (15) | 16 (30) | 0.011 |
No | 53 (56) | 17 (31) | ||
Somewhat | 28 (29) | 21 (39) | ||
Indication for Eplerenone use (n, %) | Acute | 12 (13) | 10 (19) | 0.045 |
Chronic | 62 (65) | 24 (44) | ||
Both | 21 (22) | 20 (37) | ||
Laterality consideration for Eplerenone use (n, %) | Unilateral | 2 (2) | 4 (7) | 0.189 |
Bilateral | 4 (4) | 4 (7) | ||
Doesn’t matter | 89 (94) | 46 (85) | ||
% of patients are/were on eplerenone treatment (n, %) | 0–25 | 59 (62) | 33 (61) | 0.812 |
25–50 | 20 (21) | 13 (24) | ||
50–75 | 7 (7) | 5 (9) | ||
75–100 | 9 (10) | 3 (6) | ||
Prescription of Eplerenone in the current practice (n, %) | Yes routinely | 36 (38) | 14 (26) | 0.011 |
Only when there is no response to available options | 55 (58) | 30 (56) | ||
Prescribed earlier, not now | 4 (4) | 10 (18) | ||
When to prescribe Eplerenone (n, %) | First line | 20 (21) | 16 (30) | 0.501 |
s line as monotherapy | 40 (42) | 23 (43) | ||
Third line as combination | 13 (14) | 4 (7) | ||
Desperate situations | 22 (23) | 11 (20) | ||
Daily Dose of Eplerenone (n, %) | 25 | 18 (19) | 1 (2) | 0.01 |
50 | 44 (46) | 29 (54) | ||
25–50 | 33 (35) | 24 (44) | ||
Duration of Eplerenone use (n, %) | 0–3 | 86 (91) | 51 (94) | 0.506 |
4–6 | 7 (7) | 3 (6) | ||
> 6 | 2 (2) | 0 (0) | ||
Satisfaction levels with eplerenone (n, %) | Very satisfied | 5 (5) | 1 (2) | 0.002 |
Satisfied | 50 (53) | 17 (31) | ||
Neutral | 34 (36) | 21 (39) | ||
Dissatisfied | 4 (4) | 12 (22) | ||
Very dissatisfied | 2 (2) | 3 (6) | ||
Side effects (n, %) | Renal issues | 4 (4) | 7 (13) | 0.325 |
GI disturbances | 2 (2) | 1 (2) | ||
Cardiac problem | 2 (2) | 2 (4) | ||
Muscle pain | 1 (1) | 1 (2) | ||
Generalised weakness | 1 (1) | 2 (4) | ||
Others | 2 (2) | 0 (0) | ||
Not experienced | 83 (88) | 41 (72) |